Cysview

Cysview is an FDA-registered drug product whose active ingredient is HEXAMINOLEVULINATE HYDROCHLORIDE. It is labelled by Photocure Inc. and marketed as a human prescription drug product. Identifiers on file: NDC 10511-3001, application NDA022555, label effective 20260603. This page reproduces the FDA-approved label text so you can check what a product is, who makes it and how it is supplied before discussing it with a pharmacist or prescriber.

Across FDA labelling, products containing HEXAMINOLEVULINATE HYDROCHLORIDE are most often described in connection with: bladder cancer, cystoscopic detection, including carcinoma, situ cis, adult patients, suspected known, prior cystoscopy, undergoing surveillance. Wording differs between labels, and the full indications section on this page takes precedence when it is present.

1 INDICATIONS AND USAGE CYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) based on a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer Limitations of Use CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer [see Warnings and Precautions (5.2) ] . CYSVIEW is an optical imaging agent indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) on the basis of a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer Limitations of Use CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. ( 1 , 5.2 )

2 DOSAGE AND ADMINISTRATION The recommended adult dose is 100 mg reconstituted in 50 mL of the supplied diluent instilled into the bladder via a urinary catheter and retained for 1 hour to 3 hours before evacuation. ( 2.1 ) Use an FDA-authorized blue light imaging device intended to perform blue light cystoscopy with hexaminolevulinate hydrochloride. ( 2.4 ) Perform cystosopic examination of the entire bladder first under white light and then under blue light. ( 2.5 ) For reconstitution, administration, and cystoscopic examination see full prescribing information. ( 2.2 , 2.3 , 2.5 ) 2.1 Recommended Dose The recommended dose for adults is 100 mg of CYSVIEW administered by bladder instillation. Reconstitute the CYSVIEW 100 mg powder in the vial with the supplied diluent to a final volume of 50 mL. Administer the entire 50 mL dose via a urinary catheter. The solution should be retained in the bladder for 1 hour to 3 hours following instillation. [see Dosage and Administration (2.2 , 2.3) ] . 2.2 Reconstitution of CYSVIEW General Instructions CYSVIEW is supplied as a kit with diluent for reconstitution, with or without a vial adapter for use during reconstitution [see How Supplied/Storage and Handling (16) ] . Perform all steps using aseptic technique. Wear gloves during the reconstitution procedure; skin exposure to CYSVIEW may increase the risk of sensitization to the drug. Reconstituted CYSVIEW has a concentration of 2 mg/mL hexaminolevulinate hydrochloride and appears as a colorless to pale yellow, clear to slightly opalescent solution free from visible particles. If not immediately used, store the reconstituted solution in the labeled syringe under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 2 hours. The solution should be discarded if not used within 2 hours. Reconstitution Using a Vial Adapter CYSVIEW Powder Diluent Plunger Rod Vial Adapter Figure A. Components of CYSVIEW and Attachment of Plunger Rod to Diluent Syringe 1. Fasten the plunger rod into the rubber stopper of the prefilled syringe by turning the plunger rod clockwise until it stops (see Figure A ). Figure B. Connection of Vial Adapter to CYSVIEW Vial 2. Remove the plastic cap from the vial. Remove the TyveK® cover from the vial adapter blister package. Do not remove the vial adapter from the package. Place the CYSVIEW vial on a flat surface. Using the blister package to hold the vial adapter, connect to the vial with a downward vertical motion. The vial adapter snaps onto the vial as the spike penetrates the rubber stopper of the vial. Remove the plastic blister package and discard it. Take care not to touch the exposed end of the vial adapter (see Figure B ). Figure C. Injection of Diluent into CYSVIEW Vial 3. Remove the cap from the prefilled syringe and carefully retain it for subsequent reattachment to the syringe. Hold the prefilled syringe upright and carefully press the plunger rod upward to remove air. Connect the syringe to the vial adapter. Inject about 10 mL of the diluent from the prefilled syringe down into the vial. The vial should be about ¾ full (see Figure C ). Figure D. Dissolution of CYSVIEW Powder in Diluent 4. Without disconnecting the vial adapter from the vial, hold the vial and syringe in a firm grip and gently shake to dissolve the powder in the diluent. The powder normally dissolves almost immediately (see Figure D ). Figure E. Withdrawal of Reconstituted CYSVIEW from Vial 5. Turn the vial upside down and withdraw all of the dissolved solution from the vial back into the syringe (see Figure E ). Do not inject large amounts of air or diluent when vial is inverted as it may block the venting action of the vial adapter. If this occurs, turn the vial upright and pull back on the plunger rod in the syringe. Figure F. Final Preparation of Reconstituted CYSVIEW Solution 6. Disconnect the empty vial with the vial adapter from the syringe tip and discard it. Plug the syringe with the syringe cap. Gently mix the contents of the syringe (see Figure F ). 7. Peel off the detachable portion of the syringe label. On the syringe label, add 2 hours to the present time and write the resulting expiration time and date. Reconstitution Without Using a Vial Adapter CYSVIEW Powder Diluent Plunger Rod Figure G. Components of CYSVIEW and Attachment of Plunger Rod to Diluent Syringe 1. Fasten the plunger rod into the rubber stopper of the prefilled syringe by turning the plunger rod clockwise until it stops (see Figure G ). Figure H. Injection of Diluent into CYSVIEW Vial 2. Remove the plastic cap from the vial. Remove the cap from the prefilled syringe and carefully retain it for subsequent reattachment to the syringe. Attach a needle to the prefilled syringe. Hold the prefilled syringe upright and carefully press the plunger rod upward to remove air. Penetrate the stopper of the CYSVIEW vial with the needle and inject about 10 mL of the diluent from the prefilled syringe down into the vial. The vial should be about ¾ full (see Figure H ). Figure I. Dissolution of CYSVIEW Powder in Diluent 3. Without withdrawing the needle from the vial, hold the vial and syringe in a firm grip and gently shake to dissolve of the powder in the diluent. The powder normally dissolves almost immediately (see Figure I ). Figure J. Withdrawal of Reconstituted CYSVIEW from Vial 4. Turn the vial upside down and withdraw all of the dissolved solution from the vial back into the syringe (see Figure J ). Figure K. Final Preparation of Reconstituted CYSVIEW Solution 5. Remove the needle from the vial, disconnect the needle from the syringe tip and discard it. Plug the syringe with the syringe cap. Gently mix the contents of the syringe (see Figure K ). 6. Peel off the detachable portion of the syringe label. On the syringe label, add two hours to the present time and write the resulting expiration time and date. Figure A - Powder Figure A - Diluent Figure A - Plunger Rod Figure A - Vial Adapter Figure A - Complete Figure B Figure C Figure D Figure E Figure F Figure G - Powder Figure G - Diluent Figure G - Plunger Rod Figure G Figure H Figure I Figure J Figure K 2.3 Administration Instructions Catheter Requirements For bladder instillation of the solution of CYSVIEW, use straight or intermittent, urethral catheters with a proximal funnel opening that will accommodate the Luer Lock adapter. Use only catheters made of vinyl (uncoated or coated with hydrogel), latex (amber or red), and silicone to instill the reconstituted CYSVIEW. Do not use catheters coated or embedded with silver or antibiotics. In-dwelling bladder catheters (Foley catheters) may be used if the catheters are inserted shortly prior to CYSVIEW administration and are removed following the CYSVIEW instillation. Instructions for Bladder Instillation of CYSVIEW 1. Using standard sterile catheterization technique, first insert the urethral catheter into the bladder of the patient and use the catheter to completely empty the patient's bladder before instillation of CYSVIEW. Figure L. Connection of Catheter Adapter and Instillation of CYSVIEW 2. To attach the syringe containing the solution of CYSVIEW to the catheter, do the following: Remove the syringe cap from the syringe that contains the reconstituted solution of CYSVIEW. Attach the Luer Lock end of the (provided) catheter adapter to the syringe. Insert the tapered end of the catheter adapter into the funnel opening of the catheter (see Figure L ). 3. Slowly instill the solution of CYSVIEW into the bladder through the catheter, ensuring that the complete volume of the syringe (50 mL) is administered (see Figure L ). 4. After the solution is instilled, remove the catheter and instruct the patient to retain the solution within the bladder for at least 1 hour; do not exceed 3 hours [see Dosage and Administration (2.5) ] . Patients may stand, sit and move about during the time period between instillation and start of the cystoscopic procedure. 5. Evacuate the solution of CYSVIEW from the bladder as part of routine emptying of the bladder immediately prior to the initiation of the cystoscopic procedure. Also, the patient may void and completely empty the bladder prior to the procedure. 6. Avoid skin contact with CYSVIEW. If skin does come in contact with CYSVIEW, wash immediately with soap and water and dry off. After voiding the bladder of CYSVIEW, routinely wash the patient's perineal skin region with soap and water and dry. Figure 1 2.4 Blue Light Imaging Devices Use CYSVIEW with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) System or other FDA-authorized imaging device intended to perform blue light cystoscopy (BLC) with hexaminolevulinate hydrochloride in the indicated population. The light source enables both white light cystoscopy and blue light (wavelength between 360 nm and 450 nm) fluorescence cystoscopy. For system set-up and general information for the safe use of a blue light imaging device, refer to the instruction manual for each of the system components. Certain blue light imaging devices may not be suitable for use by healthcare providers with green-red color blindness. See the instruction manual from the device manufacturer before use. 2.5 Cystoscopic Examination User Training Training and proficiency in cystoscopic procedures are essential prior to the use of CYSVIEW. Carefully review the instruction manual provided with the blue light imaging device. For additional training in the use of a blue light imaging device, contact the manufacturer's representative. CYSVIEW Administration and Cystoscopic Timing Instill CYSVIEW into the bladder and retain in the bladder for a minimum of 1 hour and a maximum of 3 hours [see Dosage and Administration (2.3) ] . Initiate the cystoscopic examination within 30 minutes after evacuation of CYSVIEW from the bladder, but no less than 1 hour or more than 3 hours after CYSVIEW instillation. If the patient did not retain CYSVIEW in the bladder for 1 hour, allow 1 hour to pass from the instillation of Cysview into the bladder to the start of the cystoscopic examination . Cystoscopic Examination with White and Blue Light Empty the patient's bladder and then fill the bladder with a clear fluid (standard bladder irrigation fluid) to distend the bladder wall. Ensure adequate irrigation during examination of the bladder; blood, urine or floating particles in the bladder can interfere with visualization under both white and blue light cystoscopy. First, perform a complete cystoscopic examination of the entire bladder using white light. If this initial examination does not reveal widespread mucosal inflammation, proceed to repeat the full examination using blue light. Under blue light, abnormal lesions typically demonstrate homogenous and intense red fluorescence with well-demarcated margins, contrasting with the blue appearance of normal urothelium. Register and map the location and appearance of any suspicious lesions or other abnormalities identified under either white or blue light. For accurate interpretation, consider the following: Less intense, more diffuse red fluorescence is expected in normal tissue at the bladder outlet and the prostatic urethra and should be distinguished from malignant lesions. To avoid false fluorescence from tangential light, hold the endoscope perpendicular and close to the bladder wall with the bladder distended. False positive fluorescence can result from scope trauma from a previous cystoscopic examination or bladder inflammation [see Warnings and Precautions (5.3) ] . Malignant lesions may not fluoresce, particularly if they are coated with necrotic tissue. Necrotic cells generally do not fluoresce [see Warnings and Precautions (5.2) ] . Avoid prolonged blue light exposure, as potential adverse effects have not been studied. In clinical trials, the cumulative blue light exposure time for evaluation, mapping, and resection did not exceed 32 minutes for any procedure [see Clinical Studies (14) ] . Only after completing white and blue light examinations and mapping should you proceed with biopsy and/or resection of suspicious lesions by transurethral resection of the bladder (TURB). Before finalizing the TURB procedure, confirm the completeness of the resections under both white and blue light.

4 CONTRAINDICATIONS CYSVIEW is contraindicated in patients with: Porphyria Known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid Porphyria Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives ( 4 )

6 ADVERSE REACTIONS The following clinically significant adverse reaction is discussed elsewhere in the Prescribing Information: Anaphylaxis [see Warnings and Precautions (5.1) ] . The most common adverse reaction was bladder spasm followed by dysuria, hematuria, and bladder pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Photocure Inc. at 1-855-297-8439 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of CYSVIEW was evaluated in 1,628 patients in seven clinical trials. Patients were aged 32 to 96 years with a median age of 70 years, 77% male, 88% White, 3% Black or African American, and 9% of unspecified racial group. All patients were evaluated after a single instillation of 100 mg of CYSVIEW, and 103 patients received a repeat administration of CYSVIEW [see Clinical Studies (14) ] . The most common adverse reaction was bladder spasm (reported in 2% of the patients) followed by dysuria, hematuria, and bladder pain. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of CYSVIEW. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Anaphylactic shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis.

What is Cysview used for?
1 INDICATIONS AND USAGE CYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) based on a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer Limitations of Use CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of …

Who makes Cysview?
Photocure Inc. is the labeler of record for Cysview.

Is Cysview prescription or over-the-counter?
The FDA label for this product is recorded as human prescription drug. Marketing status can differ between strengths and countries, so check the dispensing rules where you live.

Has Cysview been recalled?
No FDA recall record in our database matches this product name or manufacturer. Recall data is updated periodically, so a very recent notice may not appear here yet.

Where does this information come from?
All content is reproduced from FDA Structured Product Labelling data via openFDA. It is provided for identification and reference only and is not medical advice.